NASDAQ:VERU Veru Q4 2026 Earnings Date & Estimates $1.94 -0.17 (-8.06%) As of 03:58 PM Eastern This is a fair market value price provided by Massive. Learn more. Veru is estimated to report Q4 2026 earnings on Wednesday, December 16, 2026, before market opens. The conference call is scheduled for December 18, 2026 at 12:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ4 2026Announcement DateDecember 16, 2026TimeBefore Market OpensConference Call DateDecember 18, 2026Conference Call12:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Veru in Q4 2026Veru is expected to post earnings of -$0.34 per share. Veru last reported on August 10, 2026, posting -$0.30 per share and beating the -$0.32 consensus estimate. Veru has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.34Recent Track RecordLast ReportedQ3 2026Last Quarter EPS-$0.30 (Beat by +$0.02)EPS Beat Rate7 of last 8 quartersPrepare for the Q4 2026 CallEarnings HistoryCompany ProfileQ3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Veru Q4 2026 Earnings FAQ When does Veru report Q4 2026 earnings? Veru (NASDAQ:VERU) is estimated to report Q4 2026 earnings on Wednesday, December 16, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Veru's Q4 2026 earnings call? Veru's Q4 2026 earnings conference call is scheduled for Friday, December 18, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Veru? Analysts expect Veru to post earnings of -$0.34 per share for Q4 2026. When is Veru's next earnings date? Veru's next earnings date is estimated for Thursday, November 26, 2026. MarketBeat tracks confirmed and estimated earnings dates for Veru on the company's earnings history page. Veru Earnings HeadlinesVeru (VERU) Projected to Announce Quarterly Earnings on ThursdayNovember 19 at 1:10 AM | americanbankingnews.comVeru's Enobosarm Preserves Lean Mass And Physical Function In New Trial AnalysisNovember 18 at 5:55 AM | rttnews.comYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.November 20 at 1:00 AM | Reagan Gold Group (Ad)Veru Inc. Presents New Results at ObesityWeek 2026 and Provides Updates on Enobosarm Clinical TrialsNovember 17 at 12:46 PM | marketscreener.comMVeru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and ...November 17 at 12:46 PM | finance.yahoo.comVeru Inc. Reports Enobosarm Preserved Lean Mass and Physical Function in Older Obesity Patients on Semaglutide in Phase 2b QUALITY Subset AnalysisNovember 17 at 8:50 AM | quiverquant.comQSee More Veru Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email. Email Address About VeruVeru (NASDAQ:VERU) is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer. The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses. Historically, Veru was known as The Female Health Company and developed FC2, a female condom distributed in the United States and internationally. The company adopted the Veru name in 2017 as it expanded its focus into pharmaceuticals.View Veru ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.